Author Archives: Marta Figueiredo PhD

Recorlev Lessens Cushing’s Symptoms, Eases Depression, SONICS Trial Data Show

Recorlev (levoketoconazole), Strongbridge Biopharma’s oral investigational therapy, lessens disease symptoms and depression, and improves quality of life among people with endogenous Cushing’s syndrome, according to data from the Phase 3 SONICS trial. Notably, the therapy was found to particularly ease symptoms among female patients. “People with Cushing’s syndrome…

Case Series Highlights Importance of Recognizing Discrepancies Between ACTH Blood Results and Clinical Data

Recognizing discrepancies between blood tests of adenocorticotropic hormone (ACTH) levels and patients’ clinical data is important for clinicians to avoid unnecessary testing or misdiagnosis, a case series highlights. The study, “Corticotropin hormone assay interference: A case series,” was published in the journal Clinical Biochemistry. Cushing’s syndrome comprises…

New Phase 3 Data Further Support Recorlev’s Ability to Safely Lower Cortisol Levels in Cushing’s Patients

Strongbridge Biopharma released additional positive results from a Phase 3 trial evaluating whether the company’s investigational therapy Recorlev (levoketoconazole) is safe and effective for people with endogenous Cushing’s syndrome. The latest results were presented in the scientific poster “Safety and Efficacy of Levoketoconazole in Cushing Syndrome: …